JCM
UTHR icon

Jacobi Capital Management’s United Therapeutics UTHR Stock Holding History

Jacobi Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-10
Closed -$1K – 719
2016
Q4 		$1K Hold
10
– – ﹤0.01% 593
2016
Q3 		$1K Buy
+10
New +$1.2K ﹤0.01% 696

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jacobi Capital Management's UTHR Position: Q1 2017 in Review

Jacobi Capital Management sold out of United Therapeutics (UTHR) in Q1 2017, closing a stake of 10 shares — an estimated $1K sold.

Jacobi Capital Management first reported a position in UTHR in Q3 2016 and held it in 2 quarters. The position peaked at $1K in Q4 2016. 411 funds tracked by Wall St. Rank hold UTHR as of Q1 2017.

  • Jacobi Capital Management reported no remaining United Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Jacobi Capital Management sold 10 United Therapeutics shares in Q1 2017, an estimated $1K.
  • Jacobi Capital Management first reported a position in United Therapeutics in Q3 2016 and held it in 2 quarters.
  • Jacobi Capital Management's United Therapeutics position peaked at $1K in Q4 2016.
  • 411 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2017.

Based on Jacobi Capital Management's 13F filing for Q1 2017, filed 26 May 2017.